ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1857

Identification of the Long Noncoding RNA NEAT1 As a Novel Inflammatory Regulator Acting through MAPK Pathway in Human Lupus

Yuanjia Tang1, Feifei Zhang2, Bo Qu3 and Nan Shen4, 1Shanghai Institute of Rheumatology, Renji Hospital,Shanghai JiaoTong University School of Medicine, Shanghai, China, 2Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, 3Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4The Center for Autoimmune Genomics and Etiology (CAGE),Cincinnati Children’s Hospital Medical Center,Cincinnati, Ohio, United States of America, Cincinnati, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: systemic lupus erythematosus (SLE) and toll-like receptors

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Long noncoding RNAs (lncRNAs) have recently been identified to be tightly linked to diverse human diseases. This study was undertaken to investigate the contribution of the lncRNA NEAT1 which was identified to be involved in innate immune response to the pathogenesis of Systemic Lupus Erythematosus (SLE)

Methods: RT-PCR was used to compare NEAT1 expression between SLE patients and controls. Stimulation and transfection in THP-1 cells were conducted to determine the biologic function of NEAT1. Microarray and Western Blotting were performed to investigate in which pathway NEAT1 was involved. Correlation between NEAT1 expression and the disease activity of SLE patients was evaluated.

Results: NEAT1 expression was abnormally increased in the peripheral blood mononuclear cells (PBMCs) of SLE patients. We sorted the main three subsets of PBMCs (T cells, B cells, Monocytes), then compared the NEAT1 expression between SLE patients and healthy donors in these cell subsets in details and respectively. It was showed NEAT1 dominantly expressed in monocytes and was significantly up-regulated in monocytes of SLE patients compared with normal controls. Additionally, NEAT1 expression was induced by LPS via p38 activation in THP-1, the monocytic cell lines. We wondered whether or not NEAT1 would be involved in regulation of LPS-triggered induction of numerous inflammatory factors and found silencing NEAT1 significantly reduced the expression of a group of chemokines and cytokines, including IL-6, CXCL10, etc., which were induced by LPS continuously and in late stages. Furthermore, it was identified that NEAT1 selectively regulates LPS continuously-induced and late-response genes mainly through affecting the activation of the late MAPK pathway, especially the activation of JNK and ERK. Importantly, it was observed that in SLE patients, the overexpressed NEAT1 level correlates positively with the disease activity and NEAT1-regulated cytokines and chemokines.These indicate NEAT1 may be a potential contributor to the pathogenesis of lupus patients.

Conclusion: NEAT1 regulates a subset of LPS-induced inflammatory factors through affecting the activation of MAPK signaling pathway. The increased NEAT1 expression may be a potential contributor to the elevated production of a number of cytokines and chemokines in SLE patients. Our findings suggest lncRNA contributes to the pathogenesis of lupus and provides potential novel target for therapeutic intervention.


Disclosure: Y. Tang, None; F. Zhang, None; B. Qu, None; N. Shen, None.

To cite this abstract in AMA style:

Tang Y, Zhang F, Qu B, Shen N. Identification of the Long Noncoding RNA NEAT1 As a Novel Inflammatory Regulator Acting through MAPK Pathway in Human Lupus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-the-long-noncoding-rna-neat1-as-a-novel-inflammatory-regulator-acting-through-mapk-pathway-in-human-lupus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-the-long-noncoding-rna-neat1-as-a-novel-inflammatory-regulator-acting-through-mapk-pathway-in-human-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology